Изучение закономерностей эволюции гипервариабельных и консервативных участков генома ВИЧ-1
Диссертация
Определенные нуклеотидные последовательности были использованы в филогенетическом анализе. Исследуемые варианты вируса кластерируется с другими вариантами ВИЧ-1, относящимися к G субтипу. Таким образом, полимераза изучаемых вариантов вируса принадлежит субтипу G. На следующем этапе работы было проведено сравнение аминокислотных и нуклеотидных последовательностей функциональных доменов гена ОТ… Читать ещё >
Список литературы
- Бобков А.Ф., Казеннова Е. В., Селимова JI.M. Молекулярная и вирусологическая специфика эпидемии ВИЧ-инфекции в России и странах СНГ. // Вестн. Рос. Акад. Мед. Наук 2003. — С. 83−85.
- Покровский В.В., Ерамова И. Ю. и др. Внутрибольничная вспышка ВИЧ инфекции в Элисте // Ж. Микробиол.Эпидемиол. Иммунол. — 1990. — Т.4. с. 17−23.
- Ржанинова А.А. Антитела к основной нейтрализующей детерминанте вируса иммунодефицита человека. // Диссертация на соискание ученой степени кандидата биологических наук.
- Albert J. and Fenyo E.M. Simple, sensitive and specific detection of HIV-1 in clinical specimens by polymerase chain reaction with nested primers. // J.Clin. Microbiol. 1990. — V.28 — P. 1560−1564.
- Allain B, Rascle JB, de Rocquigny H, et al. CIS elements and trans-acting factors required for minus strand DNA transfer during reverse transcription of the genomic RNA of murine leukemia virus. // J Mol Biol. — 1998. — V.277. -P. 225−235.
- Amand R, Moore J, Jaffe H. et al. DNA and protein heterogeneity in serial isolates of human immunodeficiency virus (ШУ-1): indication of change in vivo.//Microbios. 1987. — V.52.-P. 191−201.
- Argos P. A sequence motif in many polymerases. Nucleic Acids Res 1988−16:9909−9916.
- Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. // J. Virol. 2001. — V.75. — P. 49 995 008.
- Bacheler L, Ploughman L, Hertogs K, Larder B. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive pateints (study DMP 266−006). // Antiviral Therapy 2000a. V.5.-P. 70.
- Bacheler LT, Anton ED, Kudish P. et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 2000b. — V.44. — P. 2475−2484.
- BackNK, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. // EMBO J. 1996. — V. 15. — P. 4040−4049.
- Baldanti F, Paolucci S, Maga G. et al. Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. //ATOS-2003.-V.17.-P. 1568−1570.
- Bedinger P, Moriarty A, von Borstel RC et al. Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. // Nature- 1988.-V.334.-P. 162−165.
- Bennetts, В. H., Teutsch, S. M., Buhler, M. M. et al. The CCR5 deletion mutation fails to protect againstmultiple sclerosis. // Human Immunology -1997.-V.58.-P. 52−59.
- Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-l coreceptors: Roles in viral entry, tropism, and disease. // Annu. Rev. Immunol. 1999. -V. 17. — P. 657−700.
- Bordier B, Tarrago-Litvak L, Sallafranque-Andreola ML. et al. Inhibition of the p66/p51 form of human immunodeficiency virus reverse transcriptase by tRNA (Lys). // Nucleic Acids Res. 1990. — V. l 1. — P. 429−436.
- Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. // J. Virol. 2002. — V.76. — P. 9143−9151.
- Brautigam С. A., Steitz Т. A. Structural and functional insights provided by crystal structures of DNA polymerases and their substrate complexes. // Curr. Opin. Struct. Biol. 1998. — V.8. — P. 54−63.
- Brenner B, Turner D, Oliveira M. et al. A V106M mutation in HIV-1 clade С viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. // AIDS 2003. — V. 17. — P. 1−5.
- Catasti P, Bradbury M. E. Gupta G. Structure and Polymorphism of HIV-1 Third Variable Loops. // J. Biol. Chem. 1996. — V.271. — №.14. — P. 8236−8242.
- Cen S, Niu M, Kleiman L. The connection domain in reverse transcriptasefacilitates the in vivo annealing of tRNALys3 to HIV-1 genomic RNA. // Retrovirology 2004. — V.19. — P.33.
- Cheng-Mayer C., Seto D., Tateno M. et al. Biologic features of HIV-1 that correlate with virulence in the host. // Science 1988. — V.240. — P. 80−82.
- Coakley E. P., Gillis J. M., Hammer S. M. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. // AIDS 2000. — V.14. — P. 9−15.
- Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. // Science 1995. — V.267. — P. 483−489.
- Connor R. I., Sheridan К. E., Ceradini D., et al. Change in coreceptor use coreceptor use correlates with disease progression in HIV-l-infected individuals. //J. of Exp. Med. 1997. — V.185. — P. 621−628.
- Das K, Ding J, Hsiou Y, et al. Crystal structures of 8-C1 and 9-C1 TIBO complexed with wild-type HIV-l RT and 8-C1 TIBO complexed with the Tyrl81Cys HIV-l RT drug-resistant mutant. // J. Mol. Biol. 1996. — V.264. -P. 1085−1111.
- De Jong J., De Ronde A., Keulen W. et al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by aingle amino acid aubstitution. // J. Virol. — 1992. V.66. — P. 6777−6780.
- De Ronde A., van Dooren M., van Der Hoek L. et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. // J. Virol. -2001.-V.75.-P. 595−602.
- Dean M., Carrington M., Winkler C. et al. Genetic restriction of HIV-l infection and progression to AIDS by a deletion allele of the CKR5 structural gene. //Science 1996.- V.273.-P. 1856−1862.
- DeClercqe E. Non nucleoside reverse transcriptase inhibitors: An overview in insights in HIV disease management. // Meniscus Health Care Commun. -1997. V.6. — P. 2—9.
- Delward E.L., Sphaer E.G., McCutchan F.E. et al. Genetic relationships determined by a heteroduplecx mobility assay: analysis of HIV env genes. // Science 1993. — V.262. -P. 1257−1261.
- Deng H, Liu R, Ellmeier W. et al., Identification of a major co-receptor for primary isolates of HIV-l. //Nature 1996. — V.20. — P. 661−666.
- Ding J., Hughes S. H., Arnold E. Proteinnucleic acid interactions and DNA conformation in a complex of human immunode®ciency virus type 1 reverse transcriptase with a double-stranded DNA template-primer. // Biopolymers -1997.-V.44.-P. 125−138.
- Doublie S. Ellenberger T. The mechanism of action of T7 DNA polymerase. // Curr. Opin. Struct. Biol. 1998. — V.8. — P. 704−712.
- Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. // J. of Gen. Virol. 2001. — V.82. — P. 1807−1814.
- Dragic Т., Trkola A., Lin S. W. et al. Amino-terminal substitutions in the CCR5 coreceptor impair gpl20 binding and human immunodeficiency virus type 1 entry. // J. Virol. 1998. — V.72. — P. 279−285.
- Druillennec S., Caneparo A., de Rocquigny H., Roques B.P. Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-l. //J. Biol. Chem. 1999. -V. 16. — P. 11 283−11 288.
- Elgavish Т., VanLoock M.S., Harvey S.C. Exploring three-dimensional structures of the HIV-l RNA/tRNALys3 initiation complex. // J. Mol. Biol. -1999.-V.285.-P. 449−453.
- Fantini J., Tamalet C., Yahi N. Secondary structure predictions of HIV-1 reverse transcriptase provide new insights into the development of drug-resistance genotypes. // AIDS 2001. — V. 15. — P. 1191−1192.
- Felsenstein J. Evolutionary trees from gene frequencies and quantitative characters: finding maximum likelihood estimates. // Evolution 1981. -V.35.-P. 1229−1242.
- Felsenstein J. Parsimony in systematics: biological and statistical issues. // Ann. Rev. ofEcol. and System. 1983. — V. 14. — P. 313−333.
- Feng Y., Broder С. C.,. Kennedy P. E, Berger E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. // Science 1996. — V.272. — P. 872−877.
- Fitzgibbon J.E., Howell R.M., Haberzettl C.A. et al. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2', 3-dideoxycytidine. // Antimicrob. Agents Chemother. -1992.-V.36.-P. 153−157.
- Fouchier R.A., Groenink M., Kootstra N.A. et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gpl20 molecule. // J. Virol. -1992. — V.66. — P. 3183−3187.
- Frost S.D., Nijhuis M., Schuurman R. et al. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. // J. Virol. 2000. — V.74. — P. 6262−6268.
- Gallego O., Corral A., de Mendoza C. et al. Prevalence of G333D/E in naive and pretreated HIV-infected patients. // AIDS Res. Hum. Retroviruses 2002. -V.18.-P. 857−860.
- Garcia-Lerma J.G., Nidtha S., Blumoff K. et al. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HTV-l from drug-naive persons. // Proc. Natl. Acad. Sci. USA 2001. — V.98. — P. 1 390 713 912.
- Gelderblom H.R. Assembly and morphology of HIV: potential effect of structure on viral function. // AIDS 1991. — V.5. — P. 617−637.
- Gomes P., Diogo I., Goncalves M.F., et al. Different pathways to nelfinavir genotypic resistance in HIV-l subtypes В and G. // 9th Conference on Retroviruses and Opportunistic Infections. 2002. — Seattle, WA. — Abst. 46
- Gonzales M.J., Wu T.D., Taylor J. et al. Extended spectrum of HIV-l reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. // AIDS 2003. — V. 17. — P. 791−799.
- Goudsmit J., Boucher C.A., Meloen R.H. et al. Human antibody response to a strain-specific HIV-l gpl20 epitope associated with cell fusion inhibition. // AIDS. 1988. — V.2. — P. 157−164.(a)
- Goudsmit J., Kuiken C.L., Nara P.L. Linear versus conformational variation of V3 neutralization domains of HIV-l during experimental and natural infection. // AIDS 1989. — V.3. — P. 119−123.
- Grant R., Liegler Т., Spotts G., Hecht F. Declining nucleoside reverse transcriptase inhibitor primary resistance in San Francisco. // Antiviral Therapy 2003. — V.8. — P. 134.
- Grossman Z., Istomin V., Averbuch D. et al. Greater genetic variation at NNRTI-associated resistance positions in patients infected by subtype C. // 10th Conference on Retroviruses and Opportunistic Infections 2003. -Boston, MA. — abst. 624
- Gurusinghe A.D., Land S.A., Birch C. et al Reverse transcriptase mutations in sequential HIV-l isolates in a patient with AIDS // J. Med. Virol. 1995. -Vol.46.-P.238−243.
- Harrigan P.R., Kinghorn I., Bloor S. et al. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility // J. Virol. 1996. — Vol.70. — P.5930−5934.
- Harrigan P.R., Wynhoven В., Montaner J. et al. Mutations at reverse transcriptase codon 103: phenotypic resistance to non-nucleoside reverse transcriptase inhibitor and clinical correlates. // Antiviral Therapy — 2003. — V.8.-P. 120.
- He J., Chen Y., Farzan M., et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. //Nature 1997. — V.385. — P. 645−649.
- Horuk R. Molecular properties of the chemokine receptor family. // Trends Pharmacol. Sci. 1994. — V.15. -P. 159−65
- Hsiou Y., Ding J., Das K. et al. The Lysl03Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. // J. Mol. Biol. 2001. — V.309. — P. 437−445.
- Huang H., Chopra R., Verdine G.L. et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. // Science 1998. — V.282. — P. 1669−1675.
- Huang W., Gamarnik A., Limoli K. et al. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. // J. Virol. -2003.-V.77.-P. 1512−1523.
- Isel C., Lanchy J., LeGrice S. F. J. et al. Specific initiation and switch to elongation of human mmunodeficiency virus type 1 reverse transcription require the post-translational modifications of primer tRNA3 Lys. // EMBO J. 1996.-V.15.-P. 917−924.
- Jacks Т., Power M.D., Masiarz F.R. et al., Characterization of ribosomal frameshifiting in HIV-1 gag-pol expression. // Nature 1988. — V.21. — P. 280−2873.
- Jacks Т., Varmus H.E. Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting. // Science 1985. — V.230. — P. 1237−1242.
- Jacobo-Molina A., Ding J., Nanni R. G et al Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA // Proc. Natl. Acad. Sci. USA 1993. — Vol.90. — P.6320−6324.
- Jiang M., Мак J., Ladha A. et al. Identification of tRNAs incorporated into wild-type and mutant human immunodeficiency virus type 1. // J. Virol. -1993.-V.67.-P. 3246−3253.
- Jordan I., Enssle J., Guttler E., et al. Expression of human foamy virus reverse transcriptase involves a spliced pol mRNA. // Virology — 1996. — V.224.-P. 314−319
- Kantor R., Katzenstein D., Camacho R. et al. Genotypic analyses of RT and protease sequences from persons infected with non-subtype В HIV-l. // 10th Conference on Retroviruses and Opportunistic Infections. 2003. — Boston, MA. — abst. 623 (a)
- Kantor R., Lee E., Johnston E., et al. Rapid flux in non-nucleoside reverse transcriptase inhibitor resistance mutations among subtype С HIV-l-infected women after single dose nevirapine. // Antiviral Therapy — 2003. V.8. P. 85. (b)
- Kellam P., Boucher C.A.B., Larder B.A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine // Proc. Natl. Acad. Sci. USA 1992.-Vol.89.-P.1934−1938.
- Keulen W., Back N.K., Boucher C.A. et al. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. // J. Virol. -1997. V.71. — P. 3346−3350.
- Keulen W., van Wijk A., Schuurman R. et al Increased polymerase fidelity of lamivudine-resistant HIV-l variants does not limit their evolutionary potential.//AIDS 1999. — V.13.-P. 1343−1349.
- Kleim J.P., Bender R., Kirsch R., et al. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. // Virology1994.-V.200.-P. 696−701.
- Kohlstaedt L.A., Wang J., Friedman J.M. et al. Crystal structure at 3.5 A resolution of HIV-l reverse transcriptase complexed with an inhibitor. // Science 1992. — V.256. P. 1783−1790.
- Lacey S.F., Larder B.A. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2', 3'-didehydro-2', 3'- dideoxythymidine in cell culture. // Antimicrob. Agents Chemother. 1994. — V.38. -P 1428−1432.
- Landman R., Schiemann R., Thiam S. et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-l-infected adults in Senegal. // AIDS 2003. -V. 17. — P. 1017−1022.
- Lanier E., Irlbeck D., Ross L., Gerondelis P. et al. Prediction of NRTI options by linking RT genotype and phenotype breakpoings. // 10th Conference on Retroviruses and Opportunistic Infections. 2003. — Boston, MA. — abst. 586
- Larder B.A., Coates K.E., Kemp S.D. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture // J. Virol. — 1991. V.65. — P.5232—5236.
- Larder В.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT) // Science 1989. — V.246. -P.l 155−1158.
- Larder B.A., Kellam P., Kemp S.D. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. // AIDS 1991.-V.5.-P. 137−144.
- Leigh Braun A J. Sequence variability in the human immunodeficiency viruses: pattern and process in viral evolution. // AIDS. — 1992. — V.6. — P. l 178−1184.
- Levy J.A. Pathogenesis of human immunodeficiency virus infection. // Microbiol. Rev. 1993. — V.57. P. 183−289.
- Lukashov V.V., Karamov E.V., Eremin V.F. et al. Extreme founder effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus. // AIDS Res. Hum. Retroviruses 1998. — V.20. — P. 1299−1303.
- Maddon P.J., McDougal J.S., Clapham P.R. et al. HIV infection does not require endocytosis of its receptor, CD4. // Cell 1988. — V.54. — P. 865−874.
- Mansky L.M. Retrovirus mutation rates and their role in genetic variation. //J. Gen. Virol. 1998.- V.79. — P. 1337−1345.
- McNearney Т., Hornickova Z., Markham R. et al. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. // Proc. Natl. Acad. Sci. USA 1992. — V.89.-P. 10 247−10 251.
- Meltzer M.S. Skillman D.R., Hoover D.L. et al. Macrophages and the human immunodeficiency virus. // Immunol Today. — 1990. V. l 1. — P. 217 223.
- Mendoza C.D., Rodriguez C., Corral A. et al. Evidence for a different transmission efficiency of viruses with distinct drug-resistant genotypes. // Antiviral Therapy 2003. -V.8. — P. 144.
- Meyer P.R., Matsuura S.E., Mian A.M. et al. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-l reverse transcriptase. // Mol. Cell 1999. — V.4. — P. 35−43.
- Miller M., Margot N., Hertogs K. et al. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. // Nucleosides Nucleotides Nucleic Acids 2001. — V.20. — P. 1025−1028.
- Miller V., Ait-Khaled M., Stone C. et al. HIV-l reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. // AIDS 2000. — V. 14. — P. 163−171.
- Montes В., Segondy M. Prevalence of the mutational pattern E44D/A and/or VI181 in the reverse transcriptase (RT) gene of HIV-l in relation to treatment with nucleoside analogue RT inhibitors. // J. Med. Virol. 2002. -V.66.-P. 299−303.
- Moore J.P., Nara P.L. The role of the V3 loop of gpl20 in HIV infection. // AIDS. 1991.-V.5.-P. 21−33.
- Morris L., Pillay C., Chezzi C., Lupondwana P. et al. Low frequency of the V106M mutation among HIV-l subtype C-infected pregnant women exposed to nevirapine. // AIDS 2003. -V. 17. — P. 1698−1700.
- Muesing M.A., Smith D.H., Cabradilla C.D. et al. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. // Nature -1985. V.7. — P. 450−458.
- O’Brien W., Koyanagi Y., Namazie A. et. al. HIV-l tropism for mononuclear phagocytes can be dermined by region of gp 120 outside the CD4-biding domain. // Nature 1998. — V.348. — P. 69−73.
- Palker T.J., Clark M.E., Langlois A.J. et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. // Proc. Natl. Acad. Sci. USA 1988. — V.85.-P. 1932−1936.
- Parikh U., Koontz D., Hammond J. et al. K65R: a multi-nucleoside resistance mutation of low but increasing frequency. // Antiviral Therapy -2003. V.8. — P. 152.
- Parkin N., Chappey C., Petropoulos C., Hellmann N. HIV-l reverse transcriptase mutations that suppress zidovudine resistance also increase in vitro susceptibility to tenofovir, but not stavudine. // Antiviral Therapy -2003. V.8. — P. 34.
- Peters G.G., Hu J. Reverse transcriptase as the major determinant for selective packaging of tRNA’s into Avian sarcoma virus particles. // J. Virol. -1980.-V.36.-P. 692−700.
- Phillips A.N., Miller V., Sabin C. et al. Durability of HIV-l viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. // AIDS 2001. — V.15. — P. 379−2384.
- Pollakis G., Abebe A., Kliphuis A. et al. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. // J. Virol. 2004. — V.78. — P. 2841−2852.
- Pollakis G., Kang S., Kliphuis A. N-Linked Glycosylation of the HIV Type-1 gpl20 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization. // J. Biol. Chem. 2001. — V.276. — P. 1 343 313 441.
- Quan Y., Gu Z., Li X. et al. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2 '-dideoxy-3 '-thiacytidine by mutated Ml84V human immunodeficiency virus type 1. // J. Virol. 1996. -V.70.-P. 5642−5645.
- Restle Т., Pawlita M., Sczakiel G. et al., Structure-function relationships of HIV-l reverse transcriptase determined using monoclonal antibodies. // J. Biol. Chem. 1992. — V.267. — P. 14 654−14 661.
- Rhee S.Y., Gonzales M.J., Kantor R. et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. // Nucleic Acids Res. — 2003.-V.31.-P. 298−303.
- Richman D.D., Havlir D., Corbeil J. et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. // J. Virol. 1994. -V.68. — P.1660−1666.
- Rini J.M., Stanfield R.L., Stura E.A. et al., Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. // Proc. Natl. Acad. Sci. USA 1993. — V.90. — P. 6325−6329.
- Rini J.M., Schulze-Gahmen U., Wilson I. A. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. // Science — 1992.-V.255.-P. 959−965.
- Rittinger K., Divita G., Goody R.S. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. // Proc. Natl. Acad. Sci. USA-1995.-V.15.-P. 8046−8049.
- Robert-Guroff M., Goedert J J., Naugle С J. et al. Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study. // AIDS Res. Hum. Retroviruses 1988. — V.4. — P. 343 350.
- Rodgers D.W., Gamblin S J., Harris B.A. et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. // Proc. Natl. Acad. Sci. USA 1995. — V.92. — P. 1222−1226.
- Ross T.M., Cullen B.R. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope VI/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. // Proc. Natl. Acad. Sci. USA 1998. — V.95. -P. 7682−7686.
- Sarafianos S.G., Clark A.D., Das K. et al. Structures of HIV-l reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. // Embo J. 2002. -V.21. -P.6614−6624.
- Sarafianos S.G., Das K., Ding J. et al. Touching the heart of HIV-l drug resistance: the fingers close down on the dNTP at the polymerase active site. //Chem. Biol. 1999. — V.6.-P. 137−146.
- Sawaya M., Prasad R, Wilson S.H. et al. Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. // Biochemistry 1997. — V.16. — P. 11 205−11 215.
- Shafer R. Genotypic Testing for HIV-l Drug Resistance In: Kuiken CL, Foley B, Hahn BH, et al. Human retroviruses and AIDS: a compilation and analysis of nucleic and amino acid sequences. 2003. -Los Alamos, NM: Los Alamos National Laboratory.
- Shulman N., Bosch R., Mellors J., Albrecht M. Genetic correlates of phenotypic hypersusceptibility to efavirenz among 446 baseline isolates from five ACTG studies. // Antiviral Therapy 2003. — V.8. — P. 48.
- Sonigo P., Alizon M., Staskus K. S. et al. Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus. // Cell 1985. — V.42. — P. 369 382.
- St. Clair M.H., Richards C.A., Spector Т., et al. 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. // Antimicrob. Agents Chemother. 1987. — V.31. — P. 1972−1977.
- Sugiura W., Matsuda Z., Yokomaku Y. et al. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. // Antimicrob. Agents Chemother. 2002. — V.46.-P. 708−715.
- Tan C.K., Civil R., Mian A.M. et al. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate. // Biochemistry — 1991. — V.30.-P. 4831—4835.
- Tantillo C., Ding J., Jacobo-Molina A. et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of
- HIV-l reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. // J. Mol. Biol. 1994. — V.243. — P. 369−387.
- Temin H.M. Reverse transcription in the eukaryotic genome: retroviruses, pararetroviruses, retro transposons, and retrotranscripts. // Mol. Biol. Evol. -1985. V.6. — P. 455−468.
- Termsmette M., Lange J.M., de Goede R.E. et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. // Lancet 1989. — V.6. — P. 983−985.
- Tisdale M., Alnadaf Т., Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. // Antimicrob. Agents Chemother. -1997.-V.41.-P. 1094−1098.
- Toni Т., Masquelier В., Bonard D. et al. Primary HIV-l drug resistance in Abidjan (Cote d’lvoire): a genotypic and phenotypic study. // AIDS 2002. — V.16.-P. 488−491.
- Topping R., Demoitie M.A., Shin N.H., Telesnitsky A. Cis-acting elements required for strong stop acceptor template selection during Moloney murine leukemia virus reverse transcription. // J. Mol. Biol. — 1998. — V.281. — P. 1— 15.
- Torti C., Gilleece Y., Hertogs K. et al. R21 IK and L214 °F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with Ml 84V. // J. Acquir. Immune Defic. Syndr. 2001. -V.26.-P. 514−515.
- Van Laethem K., Witvrouw M., Balzarini J. et al. Patient HIV-l strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. // AIDS 2000. — V. 14. — P. 469−471.
- Velazquez-Campoy A., Vega S., Freire E. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-l protease from African subtypes. // Biochemistry 2002. — V.41. — P. 8613−8619.
- Vogt M.W., Hartshorn K.L., Furman P.A. et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. // Science 1987. — V.235. — P. 1376−1379.
- Wainberg M.A., Drosopoulos W.C., Salomon H. et al. Enhanced fidelity of ЗТС-selected mutant HIV-l reverse transcriptase. // Science 1996. — V.271. -P. 1282−1285.
- Wang Z. X., Berson J. F., Zhang T. Y. et al. CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism. Unmasking of activity with M-tropic Env glycoproteins. // J. Biol. Chem. -1998. 273. — P. 15 007−15 015.
- Whitcomb J.M., Huang W., Limoli K. et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-l: clinical, phenotypic and genotypic correlates. // AIDS 2002. — V. 16. — P. 41−47.
- White-Scharf M.E., Potts B.J., Smith L.M. et al. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-l can be elicited by peptide immunization. // Virology 1993. — V.192. — P. 197−206.
- Willey R.L., Rutledge R.A., Dias S. et al. Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. // Proc. Natl. Acad. Sci. USA 1986. -V.83.-P. 5038−5042.
- Winters M.A., Merigan T.C. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs. // Antimicrob. Agents Chemother. 2001. -V.45.-P. 2276−2279.
- Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. // Science 1998. — V.280. — P. 1884−1888.
- Zack J.A., Haislip A.M., Krogstad P., Chen I. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. // J. Virol. 1992. — V.66.-P. 1717−1725.
- Zhang D., Caliendo A.M.^-Eron J J. et al. Resistance to 2', 3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. // Antimicrob. Agents Chemother. 1994. — V.38. — P. 282−287.